Skip to main navigation
Skip to search
Skip to main content
Luxembourg Institute of Health Home
Search content at Luxembourg Institute of Health
Home
Profiles
Research units
Research output
Projects
Equipment
Datasets
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Congcong Zhang
, Michael C. Burger
, Lukas Jennewein
, Sabrina Genßler
, Kurt Schönfeld
, Pia Zeiner
, Elke Hattingen
, Patrick N. Harter
, Michel Mittelbronn
, Torsten Tonn
, Joachim P. Steinbach
, Winfried S. Wels
*
*
Corresponding author for this work
Research output
:
Contribution to journal
›
Article
›
Research
›
peer-review
363
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Glioblastoma
100%
Targeted Therapy
100%
Natural Killer Cells
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
ERBB2
100%
Natural Killer
87%
Intracranial Tumor
25%
Glioblastoma Xenografts
25%
Primary Glioblastoma
25%
In Vivo Antitumor Activity
25%
Natural killer-92 Cells
25%
NSG Mice
25%
Tumor
12%
Xenograft Model
12%
Immunohistochemistry
12%
Subcutaneous Tumor
12%
Free Survival
12%
Natural Killer Cell Activity
12%
C57BL
12%
Cell Killing
12%
Primary Tumor
12%
Protein Expression
12%
Glioblastoma Cells
12%
Syngeneic
12%
Orthotopic Glioma
12%
Statistical Test
12%
In Vitro Assay
12%
Human Glioblastoma
12%
Median Survival
12%
Flow Cytometry
12%
Tumor Area
12%
Chimeric Antigen Receptor T Cells (CAR-T)
12%
Long-term Protection
12%
Tumor Immunity
12%
Immunodeficient Mice
12%
Tumor Induction
12%
Established Cell Lines
12%
Rechallenge
12%
Untargeted
12%
Primary Cell Culture
12%
Killing Activity
12%
Adoptive Immunotherapy
12%
Distant Site
12%
Local Therapy
12%
Glioblastoma Tumor
12%
Glioblastoma Cell Line
12%
Symptom-free
12%
NOD SCID
12%
Stereotactic Injection
12%
Chimeric Antigen Receptor Natural Killer Cells
12%
In Vitro Cytotoxicity Assay
12%
Immunology and Microbiology
Natural Killer Cell
100%
Xenograft
66%
NSG Mouse
66%
Antineoplastic Activity
66%
In Vitro
66%
Cytotoxicity
33%
Cell Line
33%
Syngenic
33%
Primary Cell Culture
33%
Cell Killing
33%
Protein Expression
33%
C57BL 6 Mouse
33%
Chimeric Antigen Receptor Natural Killer Cell
33%
Adoptive Immunotherapy
33%
Glioblastoma Cell Line
33%
Chimeric Antigen Receptor
33%